Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer
Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database | BMC Cancer | Full Text
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Journal of Thoracic Oncology
SciELO - Brasil - SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER
Efficacy for Newly Diagnosed Glioblastoma (GBM) | Optune®
Impact of Postoperative Radiotherapy and Chemotherapy on Survival for Patients with Node Positive Oral Cancer
5-year Overall Survival Rates by Stage at Presentation | Download Scientific Diagram
Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Efficacy Results | Myelofibrosis Clinical Trials | Jakafi HCP
A nomogram to predict overall survival for biliary tract cancer | CMAR
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink
5-year overall survival rates of Different Tumor Stages. After Log-rank... | Download Scientific Diagram
Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy | In Vivo
OA08.03 The 5-year Survival Rate of Postoperative Non-small Cell Lung Cancer Patients with Two Different Follow-up Patterns - Journal of Thoracic Oncology
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
![PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,](https://og.oa.mg/Long-Term%20(5%20Year)%20Overall%20Survival%20in%20Zuma-1,%20the%20Pivotal%20Study%20of%20Axicabtagene%20Ciloleucel%20(Axi-Cel)%20in%20Patients%20with%20Refractory%20Large%20B-Cell%20Lymphoma%20(LBCL).png?author=%20Caron%20A.%20Jacobson,%20Frederick%20L.%20Locke,%20Armin%20Ghobadi,%20David%20B.%20Miklos,%20Lazaros%20J.%20Lekakis,%20Olalekan%20O.%20Oluwole,%20Yi%20Lin,%20Brian%20T.%20Hill,%20John%20M.%20Timmerman,%20Abhinav%20Deol,%20Patrick%20M.%20Reagan,%20Patrick%20Stiff,%20Ian%20W.%20Flinn,%20Umar%20Farooq,%20Andre%20H.%20Goy,%20Javier%20Mu%C3%B1oz,%20Tanya%20Siddiqi,%20Rhine%20R%20Shen,%20Adrian%20Bot,%20Jinghui%20Dong,%20Kanwarjit%20Singh,%20Clare%20Spooner,%20Roshan%20Karalliyadda,%20Jenny%20J.%20Kim,%20Yan%20Zheng,%20Sattva%20S.%20Neelapu "PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,")
PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,
![A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2019/7837/1/fig-3-full.png "A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]")
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]
View Image
This figure shows the 5-year overall survival (OS) in 250 synovial... | Download Scientific Diagram
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer | HTML
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
